Losartan Potassium Tablet, Film Coated
Product Images NDC 68788-8186

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-8186). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tab Usp 100mg (C4b81f90 Bcd0 45d0 99ce 35ca998d473a 00)

Losartan is a prescription medication used to treat high blood pressure. The drug comes in the form of tablet and contains 100mg of Losartan potassium. It is manufactured by Solco Healthcare U.S., LLC and is a generic version of Cozaar. The package size and expiration date are also mentioned. The medication should not be transferred to anyone other than the patient it was prescribed for, as it is prohibited by federal law.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

FDA Label Image

Figure 1 (Spl Image2 Figure1)

This appears to be a comparison between two medications - Atenolol and Losartan Potassium - in terms of their effectiveness in reducing the risk of an unspecified primary endpoint. The text mentions an adjusted risk reduction of 13% with a p-value of 0.021, implying that Losartan Potassium may be more effective than Atenolol. The graph shows the study month timeline from 0 to 66, indicating that the study was conducted for at least 5 years.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

This text provides information about the adjusted risk reduction of a medication called Atenolol and its equivalence to another medication called Losartan Potassium. The risk reduction percentage is shown to be 25% with a p-value of 0.001. Additionally, there is a graph that indicates the percentage of patients with fatal/non-fatal stroke at different study months ranging from 6 to 66.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

The text describes the results of a clinical trial regarding the primary endpoint events within demographic subgroups. The trial evaluated the effectiveness of Losartan potassium compared to Atenolol on stroke prevention in patients. The results are presented in a table that includes the number of events, patient rates, and hazard ratios for different subgroups (based on age, gender, race, ISH, diabetes, and history of CVD). The symbols in the table are proportional to the sample size. The study was adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

This is a graph showing the percentage of patients experiencing an event while taking Losartan Potassium versus Placebo over a period of 48 months. The Risk Reduction for Losartan Potassium is 16.1%, with a p-value of 0.022. There are no other readable details available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.